Overview

Clinical Study of Camrelizumab Combined With APatinib and Albumin Paclitacxel in Patients With Advanced Lung Adenocarcinoma

Status:
Not yet recruiting

Trial end date:
2023-07-15

Target enrollment:

Participant gender:

Summary

This study is a single arm, open label, national multicenter study, to explore the efficacy and safety of the combination of Camrelizumab, apatinib and albumin paclitaxel in advanced untreated EGFR Wild Type and ALK-negative Lung Adenocarcinoma. The study does not consider PD-L1 expression, but tumor samples need to be explored by PD-L1 detection and other exploratory analysis.

Phase:

Phase 2

Details

Lead Sponsor:

Hunan Cancer Hospital

Collaborator:

Suzhou Sheng Diya Biomedical Co., Ltd.

Treatments:

Apatinib
Immune Checkpoint Inhibitors